메뉴 건너뛰기




Volumn 180, Issue 2, 1999, Pages 290-298

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

(15)  Evans, Thomas G a,n   Keefer, Michael C a   Weinhold, Kent J c   Wolff, Mark o   Montefiori, David c   Gorse, Geoffrey J f   Graham, Barney S g   McElrath, M Juliana h   Clements Mann, Mary Lou d   Mulligan, Mark J i   Fast, Patricia e,l   Walker, Mary Clare e   Excler, Jean Louis j,m   Duliege, Ann Marie k   Tartaglia, James b  


Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

EID: 0033496071     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314895     Document Type: Article
Times cited : (170)

References (49)
  • 1
    • 0030593031 scopus 로고    scopus 로고
    • Toward an understanding of the correlates of protective immunity to HIV infection
    • 1. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection [see comments]. Science 1996; 271:324-8.
    • (1996) Science , vol.271 , pp. 324-328
    • Haynes, B.F.1    Pantaleo, G.2    Fauci, A.S.3
  • 2
    • 0028839622 scopus 로고
    • Candidate AIDS vaccines
    • 2. Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med 1995;333: 1331-9.
    • (1995) N Engl J Med , vol.333 , pp. 1331-1339
    • Graham, B.S.1    Wright, P.F.2
  • 3
    • 17344365609 scopus 로고    scopus 로고
    • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
    • AIDS Vaccine Evaluation Group
    • 3. Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:301-9.
    • (1998) J Infect Dis , vol.177 , pp. 301-309
    • Corey, L.1    McElrath, M.J.2    Weinhold, K.3
  • 4
    • 0029054368 scopus 로고
    • Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
    • 4. Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995;171: 1623-7.
    • (1995) J Infect Dis , vol.171 , pp. 1623-1627
    • Egan, M.A.1    Pavlat, W.A.2    Tartaglia, J.3
  • 5
    • 0028986509 scopus 로고
    • A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/ LAI)
    • The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995;11:875]
    • 5. Pialoux G, Excler JL, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/ LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995;11:875]. AIDS Res Hum Retroviruses 1995;11:373-81.
    • (1995) AIDS Res Hum Retroviruses , vol.11 , pp. 373-381
    • Pialoux, G.1    Excler, J.L.2    Riviere, Y.3
  • 6
    • 0026492569 scopus 로고
    • + cytolytic t lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
    • + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-42.
    • (1992) J Exp Med , vol.176 , pp. 1531-1542
    • Hammond, S.A.1    Bollinger, R.C.2    Stanhope, P.E.3
  • 8
    • 0029160880 scopus 로고
    • A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees
    • 8. Perales MA, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:27-35.
    • (1995) J Acquir Immune Defic Syndr Hum Retrovirol , vol.10 , pp. 27-35
    • Perales, M.A.1    Schwartz, D.H.2    Fabry, J.A.3    Lieberman, J.4
  • 9
    • 19244362119 scopus 로고    scopus 로고
    • Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a rccombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160
    • 9. Fleury B, Janvier G, Pialoux G, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a rccombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174: 734-8.
    • (1996) J Infect Dis , vol.174 , pp. 734-738
    • Fleury, B.1    Janvier, G.2    Pialoux, G.3
  • 10
    • 0031039054 scopus 로고    scopus 로고
    • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
    • 10. McElrath MJ, Siliciano RF, Weinhold KJ. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-6.
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 211-216
    • McElrath, M.J.1    Siliciano, R.F.2    Weinhold, K.J.3
  • 11
    • 7144259087 scopus 로고    scopus 로고
    • Immune responses to human immunodenciency virus (HIV) type 1 induced by canarypox expressing HIV-IMN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
    • NIAID AIDS Vaccine Evaluation Group
    • 11. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodenciency virus (HIV) type 1 induced by canarypox expressing HIV-IMN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
    • (1998) J Infect Dis , vol.177 , pp. 1230-1246
    • Clements-Mann, M.L.1    Weinhold, K.2    Matthews, T.J.3
  • 12
    • 7844229165 scopus 로고    scopus 로고
    • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 sf-2 recombinant vaccines in uninfected volunteers
    • NIAID AIDS Vaccine Evaluation Group
    • 12. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-15.
    • (1998) AIDS , vol.12 , pp. 2407-2415
    • Belshe, R.B.1    Gorse, G.J.2    Mulligan, M.J.3
  • 14
    • 0030869489 scopus 로고    scopus 로고
    • Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-I altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides
    • 14. Sewell AK, Harcourt GC, Goulder PJ, Price DA, Phillips RE. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-I altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur J Immunol 1997;27:2323-9.
    • (1997) Eur J Immunol , vol.27 , pp. 2323-2329
    • Sewell, A.K.1    Harcourt, G.C.2    Goulder, P.J.3    Price, D.A.4    Phillips, R.E.5
  • 15
    • 0029046706 scopus 로고
    • Immunogenic HIV variant peptides that bind to HLA-BS can fail to stimulate cytotoxic T lymphocyte responses
    • 15. McAdam S, Klenerman P, Tussey L, et al. Immunogenic HIV variant peptides that bind to HLA-BS can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-36.
    • (1995) J Immunol , vol.155 , pp. 2729-2736
    • McAdam, S.1    Klenerman, P.2    Tussey, L.3
  • 16
    • 16944365445 scopus 로고    scopus 로고
    • Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
    • 16. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [see comments]. Nat Med 1997;3:205-11.
    • (1997) Nat Med , vol.3 , pp. 205-211
    • Borrow, P.1    Lewicki, H.2    Wei, X.3
  • 17
    • 0029006397 scopus 로고
    • The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus
    • 17. Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995;25: 1927-31.
    • (1995) Eur J Immunol , vol.25 , pp. 1927-1931
    • Klenerman, P.1    Meier, U.C.2    Phillips, R.E.3    McMichael, A.J.4
  • 18
    • 0027462887 scopus 로고
    • Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
    • 18. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-6.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 1882-1886
    • Cooney, E.L.1    McElrath, M.J.2    Corey, L.3
  • 19
    • 0027404328 scopus 로고
    • Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
    • The NIAID AIDS Vaccine Clinical Trials Network
    • 19. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993; 167:533-7.
    • (1993) J Infect Dis , vol.167 , pp. 533-537
    • Graham, B.S.1    Matthews, T.J.2    Belshe, R.B.3
  • 20
    • 0027968518 scopus 로고
    • Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus
    • The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network
    • 20. Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis 1994;170:782-6.
    • (1994) J Infect Dis , vol.170 , pp. 782-786
    • Graham, B.S.1    Gorse, G.J.2    Schwartz, D.H.3
  • 22
    • 0023927549 scopus 로고
    • + T helper cell function in vivo: Differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
    • + T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses. J Virol 1988;62:2102-6.
    • (1988) J Virol , vol.62 , pp. 2102-2106
    • Ahmed, R.1    Butler, L.D.2    Bhatti, L.3
  • 23
    • 0031204408 scopus 로고    scopus 로고
    • The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
    • 23. Livingston BD, Crimi C, Grey H, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997;159:1383-92.
    • (1997) J Immunol , vol.159 , pp. 1383-1392
    • Livingston, B.D.1    Crimi, C.2    Grey, H.3
  • 24
    • 0029966723 scopus 로고    scopus 로고
    • Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides
    • 24. Sauzet JP, Gras-Masse H, Guillet JG, Gomard E. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Int Immunol 1996;8:457-65.
    • (1996) Int Immunol , vol.8 , pp. 457-465
    • Sauzet, J.P.1    Gras-Masse, H.2    Guillet, J.G.3    Gomard, E.4
  • 25
    • 0025817991 scopus 로고
    • Normal development and function of CD8' cells but markedly decreased helper cell activity in mice lacking CD4
    • 25. Rahemtulla A, Fung-Leung WP, Schilham MW, et al. Normal development and function of CD8' cells but markedly decreased helper cell activity in mice lacking CD4. Nature 1991;353:180-4.
    • (1991) Nature , vol.353 , pp. 180-184
    • Rahemtulla, A.1    Fung-Leung, W.P.2    Schilham, M.W.3
  • 26
    • 0030986358 scopus 로고    scopus 로고
    • A critical role for neutralizing-antibody-producing B cells, CD4(') T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
    • 26. Planz O, Ehl S, Furrer E, et al. A critical role for neutralizing-antibody-producing B cells, CD4(') T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997;94:6874-9.
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 6874-6879
    • Planz, O.1    Ehl, S.2    Furrer, E.3
  • 27
    • 0018581317 scopus 로고
    • The effect of specific antibody on the generation of cytotoxic T lymphocytes and the recovery of mice from influenza virus infection
    • 27. Yap KL, Ada GL. The effect of specific antibody on the generation of cytotoxic T lymphocytes and the recovery of mice from influenza virus infection. Scand J Immunol 1979;10:325-32.
    • (1979) Scand J Immunol , vol.10 , pp. 325-332
    • Yap, K.L.1    Ada, G.L.2
  • 28
    • 0022468614 scopus 로고
    • Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse
    • 28. Bangham CR. Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology 1986;59:37-41.
    • (1986) Immunology , vol.59 , pp. 37-41
    • Bangham, C.R.1
  • 29
    • 0029197894 scopus 로고
    • The safety and use of canarypox vectored vaccines
    • 29. Plotkin SA, Cadoz M, Meignier B, et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995;84:165-70.
    • (1995) Dev Biol Stand , vol.84 , pp. 165-170
    • Plotkin, S.A.1    Cadoz, M.2    Meignier, B.3
  • 30
    • 0026762697 scopus 로고
    • Immunisation with canarypox virus expressing rabies glycoprotein
    • 30. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein (see comments). Lancet 1992;339:1429-32.
    • (1992) Lancet , vol.339 , pp. 1429-1432
    • Cadoz, M.1    Strady, A.2    Meignier, B.3
  • 31
    • 0029957222 scopus 로고    scopus 로고
    • Applications of pox virus vectors to vaccination: An update
    • 31. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-53.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 11349-11353
    • Paoletti, E.1
  • 32
    • 0029947256 scopus 로고    scopus 로고
    • Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative pox-virus vector system
    • 32. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative pox-virus vector system. Vaccine 1996;14:428-34.
    • (1996) Vaccine , vol.14 , pp. 428-434
    • Fries, L.F.1    Tartaglia, J.2    Taylor, J.3
  • 33
    • 0028997136 scopus 로고
    • Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species
    • 33. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995;13:539-49.
    • (1995) Vaccine , vol.13 , pp. 539-549
    • Taylor, J.1    Meignier, B.2    Tartaglia, J.3
  • 34
    • 0027988552 scopus 로고
    • Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non HIV-infected human volunteers
    • 34. Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non HIV-infected human volunteers. J Infect Dis 1994;170:1288-91.
    • (1994) J Infect Dis , vol.170 , pp. 1288-1291
    • Kahn, J.O.1    Sinangil, F.2    Baenziger, J.3
  • 35
    • 9244255773 scopus 로고    scopus 로고
    • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
    • NIAID AIDS Vaccine Evaluation Group
    • 35. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996;12:683-93.
    • (1996) AIDS Res Hum Retroviruses , vol.12 , pp. 683-693
    • Keefer, M.C.1    Graham, B.S.2    McElrath, M.J.3
  • 36
    • 0030967937 scopus 로고    scopus 로고
    • Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
    • 36. Keefer MC, Wolff M, Gorse GJ, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997;13: 1163-77.
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 1163-1177
    • Keefer, M.C.1    Wolff, M.2    Gorse, G.J.3
  • 37
    • 0027178289 scopus 로고
    • Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
    • 37. Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
    • (1993) Lancet , vol.342 , pp. 69-73
    • Schwartz, D.H.1    Gorse, G.2    Clements, M.L.3
  • 38
    • 0030764685 scopus 로고    scopus 로고
    • Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
    • 38. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:924-32.
    • (1997) J Infect Dis , vol.176 , pp. 924-932
    • Pilgrim, A.K.1    Pantaleo, G.2    Cohen, O.J.3
  • 39
    • 0013680466 scopus 로고    scopus 로고
    • + CTL induced in AIDS Vaccine Evaluation Group phase 1 trials using canarypox vectors (AL-VAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost
    • Geneva
    • + CTL induced in AIDS Vaccine Evaluation Group phase 1 trials using canarypox vectors (AL-VAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. 12th World Conference AIDS, Geneva, 1998.
    • (1998) 12th World Conference AIDS
    • Evans, T.G.1    Corey, L.2    Clements-Mann, M.L.3
  • 40
    • 0004510030 scopus 로고
    • The HLA-class I-restricted CTL response in HIV-1 infection; identification of optimal epitopes
    • Los Alamos National Laboratory, Los Alamos, NM: IV-1-IV-8
    • 40. Brander C, Walker BD. The HLA-class I-restricted CTL response in HIV-1 infection; identification of optimal epitopes. HIV Molecular Immunology Database, 1995; Los Alamos National Laboratory, Los Alamos, NM: IV-1-IV-8.
    • (1995) HIV Molecular Immunology Database
    • Brander, C.1    Walker, B.D.2
  • 41
    • 0013664814 scopus 로고    scopus 로고
    • Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines
    • Park City, UT
    • 41. Ferrari G, Humphrey W, Corr K, et al. Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines. Keystone Symposium on HIV Pathogenesis and Treatment, Park City, UT, 1998.
    • (1998) Keystone Symposium on HIV Pathogenesis and Treatment
    • Ferrari, G.1    Humphrey, W.2    Corr, K.3
  • 42
    • 19144365910 scopus 로고    scopus 로고
    • Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
    • The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
    • 42. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-8.
    • (1996) J Infect Dis , vol.173 , pp. 340-348
    • Mascola, J.R.1    Snyder, S.W.2    Weislow, O.S.3
  • 43
    • 16944367422 scopus 로고    scopus 로고
    • Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
    • 43. Zolla-Pazner S, Alving C, Bclshe R, et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines [see comments]. J Infect Dis 1997;175:764-74.
    • (1997) J Infect Dis , vol.175 , pp. 764-774
    • Zolla-Pazner, S.1    Alving, C.2    Bclshe, R.3
  • 44
    • 0030586434 scopus 로고    scopus 로고
    • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial
    • NIAID AIDS Vaccine Evaluation Group
    • 44. Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996;125:270-9.
    • (1996) Ann Intern Med , vol.125 , pp. 270-279
    • Graham, B.S.1    Keefer, M.C.2    McElrath, M.J.3
  • 45
    • 0031037693 scopus 로고    scopus 로고
    • Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
    • 45. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Prat Natl Acad Sci USA 1997;94:1396-401.
    • (1997) Prat Natl Acad Sci USA , vol.94 , pp. 1396-1401
    • Ferrari, G.1    Humphrey, W.2    McElrath, M.J.3
  • 46
    • 0029847966 scopus 로고    scopus 로고
    • + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes
    • + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996;70:8165-8.
    • (1996) J Virol , vol.70 , pp. 8165-8168
    • Posavad, C.M.1    Koelle, D.M.2    Corey, L.3
  • 48
    • 0029793618 scopus 로고    scopus 로고
    • Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes
    • 48. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996;70:5799-806.
    • (1996) J Virol , vol.70 , pp. 5799-5806
    • Yang, O.O.1    Kalams, S.A.2    Rosenzweig, M.3
  • 49
    • 0032556872 scopus 로고    scopus 로고
    • HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
    • 49. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;191:397-401.
    • (1998) Nature , vol.191 , pp. 397-401
    • Collins, K.L.1    Chen, B.K.2    Kalams, S.A.3    Walker, B.D.4    Baltimore, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.